Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15637
|
| Title: | Characterization of chicken-derived antibody against Alpha-Enolase of Streptococcus pneumoniae |
| Other Titles: | Characterization of chicken-derived antibody against α-Enolase of Streptococcus pneumoniae |
| Authors: | Lee, CH;Wu, CJ;Yang, YY;Wang, WC;Leu, SJ;Wu, CT;Kao, PS;Liu, KJ;Tsai, BY;Chiang, YW;Mao, YC;Benedict Dlamini, N;Chang, J |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Streptococcus pneumoniae is a clinically relevant pathogen notorious for causing pneumonia, meningitis, and otitis media in immunocompromised patients. Currently, antibiotic therapy is the most efficient treatment for fighting pneumococcal infections. However, an arise in antimicrobial resistance in S. pneumoniae has become a serious health issue globally. To resolve the problem, alternative and cost-effective strategies, such as monoclonal antibody-based targeted therapy, are needed for combating bacterial infection. S. pneumoniae alpha-enolase (spEno1), which is thought to be a great target, is a surface protein that binds and converts human plasminogen to plasmin, leading to accelerated bacterial infections. We first purified recombinant spEno1 protein for chicken immunization to generate specific IgY antibodies. We next constructed two single-chain variable fragments (scFv) antibody libraries by phage display technology, containing 7.2 × 107 and 4.8 × 107 transformants. After bio-panning, ten scFv antibodies were obtained, and their binding activities to spEno1 were evaluated on ELISA, Western blot and IFA. The epitopes of spEno1 were identified by these scFv antibodies, which binding affinities were determined by competitive ELISA. Moreover, inhibition assay displayed that the scFv antibodies effectively inhibit the binding between spEno1 and human plasminogen. Overall, the results suggested that these scFv antibodies have the potential to serve as an immunotherapeutic drug against S. pneumoniae infections. |
| Date: | 2024-02-15 |
| Relation: | International Immunopharmacology. 2024 Feb 15;128:Article number 111476. |
| Link to: | http://dx.doi.org/10.1016/j.intimp.2023.111476 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1567-5769&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001154442200001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181811612 |
| Appears in Collections: | [劉柯俊] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85181811612.pdf | | 5575Kb | Adobe PDF | 64 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
